Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.
Lakewood-Amedex Biotherapeutics Price Performance
Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 on Monday, reaching $0.22. The company’s stock had a trading volume of 828,332 shares, compared to its average volume of 7,485,027. The firm has a market capitalization of $519,978.00 and a P/E ratio of -0.05. The business has a 50-day simple moving average of $0.99. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the stock. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, HC Wainwright initiated coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Wednesday, October 28th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Lakewood-Amedex Biotherapeutics presently has a consensus rating of “Hold”.
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Featured Articles
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
